Hormone websites often use reassuring words that describe different aspects of a medicine. A treatment can be bioidentical and FDA-approved, or bioidentical and compounded. Reading those terms as opposites can make a comparison unnecessarily confusing.
This guide uses FDA, ACOG and The Menopause Society information checked September 22, 2026. It explains the evidence and regulatory questions to discuss with a prescriber, without deciding that any particular product is suitable for an individual.
Begin with the finished medicine
Ask for the exact name, ingredients, strength, route and manufacturer or compounding pharmacy. A discussion about estrogen in general cannot establish all the properties of a particular cream, tablet or patch. The finished product and its intended use are the things to identify.
An approved ingredient does not automatically mean that every preparation made from it is an FDA-approved finished drug. Likewise, a pharmacy license or a provider’s quality statement is not a substitute for product approval.
What FDA approval contributes
FDA-approved medicines undergo a review process involving evidence about safety, effectiveness and quality for their approved uses. Approval does not mean no risks exist or that the product is appropriate for everyone. It gives a different evidence and regulatory starting point from a custom preparation.
Some approved estrogen and progesterone medicines are bioidentical. That word refers to hormone structure; it does not require compounding. The HRT basics guide introduces the broader clinical decisions about route, symptoms and accompanying treatment.
What compounding means for the comparison
Compounding can be used to prepare a medicine for an individual need, but compounded drugs are not FDA-approved. FDA does not review them before marketing for safety, effectiveness and quality in the same way as approved products. That is an important difference to discuss rather than obscure with a general claim about personalization.
Ask why an available approved product would not meet the need being addressed. ACOG and The Menopause Society do not support claims that compounded menopause hormones are inherently safer or more effective than approved alternatives. A lower price or a different texture does not establish a clinical advantage.
Keep the claim attached to the correct product
For example, the Winona review distinguishes products identified as approved in its FAQ from compounded creams. The Noom review makes a similar distinction within another offer. One company can discuss both categories without every product acquiring the same status.
Do not transfer evidence from one hormone formulation or route to a different combination without a clinical explanation. A published ingredient study is not automatically a study of a provider’s exact compounded product or care program.
Questions worth asking before filling the prescription
Request the reason for the proposed product, available alternatives, relevant risks, monitoring plan and what to do if there is a problem. Ask the pharmacist to explain the supplied label and any handling instructions. Keep the written answer with the treatment record.
The appointment planner includes a question about approval and compounding. The point is not to become your own regulator or prescriber. It is to understand what you are being offered, which evidence applies and why the clinician believes that particular choice fits your situation.
THE READING BEHIND THE ARTICLE
Sources & reading notes
Provider pages describe their own services and commercial terms. They are not independent evidence of better clinical results. Prices and access can change.
- FDA: understanding the risks of compounded drugs ↗
- ACOG: hormone therapy for menopause ↗
- The Menopause Society: hormone therapy ↗
Checked September 22, 2026. Our editorial process · Promotion disclosure. This article is educational and cannot determine which treatment is right for you.